Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

A study published in Nature Communications examined the use of calcium carbonate nanoparticles (CNPs) to improve the activation and function of cytotoxic T lymphocytes (CTLs) in cancer immunotherapy.